Hemorrhoid Treatment Devices Market By Product Type (Band Ligators, Infrared Coagulators, Sclerotherapy Devices, Cryotherapy Devices, Electrosurgical Equipment, Doppler-Guided Systems); By Procedure (Non-Surgical, Minimally Invasive Surgical, Conventional Surgery); By End User (Hospitals, ASCs, Specialty Clinics); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Hemorrhoid Treatment Devices Market will witness a robust CAGR of 13.2 % , valued at USD 795.3 million in 2024 , and is expected to appreciate and reach USD 1.66 billion by 2030 , confirms Strategic Market Research.

 

Hemorrhoids , or swollen veins in the lower rectum and anus, affect millions globally, with increasing prevalence among aging populations, sedentary lifestyle communities, and pregnant women. As awareness around treatment options improves and stigma surrounding the condition declines, the demand for minimally invasive and device-based treatments is accelerating. The market for hemorrhoid treatment devices encompasses instruments and equipment used in procedures such as rubber band ligation, infrared coagulation, cryotherapy, sclerotherapy, and Doppler-guided hemorrhoidal artery ligation.

 

Strategic Relevance (2024–2030)

This market sits at the intersection of key macro healthcare trends. The growing global burden of colorectal disorders, alongside increased outpatient procedural care, is driving up the utilization of hemorrhoid treatment devices. The transition from open surgical approaches to less-invasive outpatient procedures is pivotal, offering both clinical efficiency and cost-effectiveness. Additionally, favorable reimbursement policies in developed markets and the increasing presence of ambulatory surgical centers (ASCs) across emerging economies amplify the demand trajectory.

 

Key Macro Drivers

• Technological Advancements: Innovations in laser therapy and radiofrequency-based devices are enabling more targeted, pain-free treatments with faster recovery times.

• Aging Global Population: Incidence rates of hemorrhoids are directly correlated with age, particularly in those over 50.

• Shifting Lifestyle Patterns: Increased obesity rates, chronic constipation, and low- fiber diets are major contributing factors to hemorrhoidal disorders worldwide.

• Healthcare Decentralization: Growth in ASCs and outpatient surgical settings globally is expanding procedural access beyond tertiary care hospitals.

• Government-Led Awareness Campaigns: Public health agencies in several nations are promoting early diagnosis and minimally invasive treatments to reduce chronic complications.

 

Key stakeholders in this market include:

• Medical device manufacturers focusing on innovative endoscopic and non-invasive product lines

• Hospitals and outpatient clinics integrating advanced hemorrhoid treatment technologies

• Gastroenterologists and colorectal surgeons adopting new procedural techniques

• Payers and insurers influencing treatment adoption through reimbursement frameworks

• Public health bodies and regulators shaping device approvals and usage protocols

• Private investors and venture capitalists funding next-gen treatment platforms in digestive health

The convergence of rising incidence, evolving treatment preferences, and supportive regulatory landscapes makes the hemorrhoid treatment devices market a strategically critical space for innovation and investment over the next decade.

 

Market Segmentation And Forecast Scope

The hemorrhoid treatment devices market is structured across four primary dimensions: By Product Type , By Procedure , By End User , and By Region . These segments provide critical insight into adoption trends, innovation opportunities, and strategic investment pockets.

By Product Type

This dimension categorizes devices based on their core mechanism of action. Common types include:

• Band Ligators (Rubber Band Ligation Devices)

• Infrared Coagulators

• Sclerotherapy Injection Devices

• Cryotherapy Devices

• Electrosurgical Equipment

• Doppler-Guided Hemorrhoidal Artery Ligation (DG-HAL) Systems

Among these, band ligators held the highest share in 2024 , accounting for over 34% of the total market, driven by their affordability, outpatient applicability, and lower complication rates. However, infrared coagulators are projected to be the fastest-growing sub-segment, with their non-contact approach increasingly preferred in ambulatory surgical centers .

“With patients demanding faster recovery and minimal downtime, device manufacturers are pivoting towards non-invasive and light-based modalities,” explains a colorectal device product manager at a U.S.-based OEM.

 

By Procedure

Procedural segmentation is critical to understanding treatment utilization and device compatibility. The primary categories include:

• Non-Surgical Procedures (e.g., Rubber Band Ligation, IRC, Sclerotherapy)

• Minimally Invasive Surgical Procedures (e.g., DG-HAL, Stapled Hemorrhoidopexy )

• Conventional Hemorrhoidectomy

The non-surgical category dominates due to its widespread application in outpatient settings and ability to manage early-stage hemorrhoids . As the focus shifts toward day-case procedures and avoidance of general anesthesia , device-based non-surgical options are expected to capture a larger share of the procedural mix by 2030.

 

By End User

Device adoption is also driven by the type of healthcare facility:

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Specialty Clinics and Colorectal Centers

Hospitals remain the largest end-user segment as of 2024. However, ASCs are the fastest-expanding channel, especially in the U.S., Germany, and South Korea, where procedural volumes are shifting due to cost constraints and patient preference.

“ASCs offer higher turnover rates and reduced wait times, making them an ideal venue for device-based hemorrhoid treatments,” notes a European healthcare operations analyst.

 

By Region

The global market is broken down into:

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

Regional dynamics, insurance models, procedural cost benchmarks, and device approval timelines vary significantly across these geographies and will be elaborated in Section 5.

 

Market Trends And Innovation Landscape

The hemorrhoid treatment devices market is experiencing a wave of innovation driven by evolving patient expectations, emerging technologies, and procedure-specific customization. Over the forecast period (2024–2030), manufacturers are increasingly investing in minimally invasive solutions that promise enhanced comfort, reduced downtime, and minimal post-procedural complications.

1. Technological Advancement in Minimally Invasive Devices

Modern hemorrhoid treatment is rapidly transitioning from surgical excision to device-assisted, office-based therapies. Notable advancements include:

• Infrared Coagulation (IRC) Platforms with adjustable heat signatures and disposable fiber tips for safer application.

• Cryotherapy Probes equipped with real-time tissue monitoring and temperature control mechanisms.

• Radiofrequency and Bipolar Coagulation Devices that offer targeted cauterization with minimal tissue damage.

These technologies reduce the need for hospitalization and allow treatments to be performed in under 15 minutes, significantly improving throughput for care providers.

“The future lies in precision-guided thermal ablation devices that require no anesthesia and offer same-day discharge,” comments a senior R&D lead at a German endoscopic systems company.

 

2. Digital Integration and Smart Device Interfaces

Emerging players are developing smart hemorrhoid treatment systems with digital interfaces, allowing physicians to calibrate device output based on hemorrhoid grade, tissue density, and patient feedback in real time. Integration with electronic health records (EHR) and treatment planning software is also gaining traction, particularly in the U.S. and Japan.

“Smart consoles with procedural analytics will drive standardization and enable predictive treatment planning,” notes a U.S. clinical technologist.

 

3. Disposable and Single-Use Trends

Infection control and cross-contamination concerns have led to a strong push for single-use applicators and pre-sterilized ligators . This trend is particularly prominent in outpatient clinics and ASCs, which operate under strict turnover and hygiene metrics.

Manufacturers are focusing on ergonomic, disposable kits that can be easily integrated into diverse clinical workflows, minimizing the burden of sterilization logistics.

 

4. R&D and Innovation Partnerships

Several companies are entering strategic R&D alliances with academic institutions and clinical research organizations to co-develop the next generation of hemorrhoid management tools. These include:

• Prototyping of robotic ligation arms for extreme precision

• Development of multi-modality devices that combine coagulation and ligation

• Clinical validation of customizable treatment protocols based on AI-backed hemorrhoid staging systems

 

5. Regulatory Approvals and Expansion Pathways

Global regulatory bodies like the FDA , CE , and TGA are accelerating approval pathways for low-risk Class II devices, particularly those that improve access and reduce cost. This has opened doors for mid-sized firms to bring innovative, cost-effective devices to market, intensifying competitive diversity.

 

Competitive Intelligence And Benchmarking

The global hemorrhoid treatment devices market is moderately consolidated, with a mix of legacy medtech manufacturers and emerging innovators. Competition is largely driven by technological differentiation , procedural efficiency , cost-effectiveness , and regulatory reach . Companies are diversifying their portfolios to address growing demand in both surgical and non-surgical hemorrhoid care pathways.

1. Medtronic As a global medtech leader, Medtronic leverages its vast electrosurgical product ecosystem to support hemorrhoidal interventions, especially in minimally invasive surgery settings. The company emphasizes standardized treatment protocols , integration with visualization tools, and distribution through large hospital networks. Its devices are widely used in stapled hemorrhoidopexy and electrocoagulation-based therapies .

 

2. Cook Medical Cook Medical is a pioneer in non-surgical hemorrhoid management . Its ligation systems and anoscopic tools are widely adopted in GI clinics across North America and Europe. The company’s competitive edge lies in disposable instrumentation and procedure-specific kits that support rapid outpatient workflows.

 

3. Boston Scientific While known more broadly for cardiovascular and urological devices, Boston Scientific has entered this space through acquisition and internal R&D. It is investing in multi-functional endoscopic platforms that integrate hemorrhoidal therapy capabilities, particularly targeting hospital-based GI suites .

 

4. Privi Medical A startup -turned-scaler, Privi Medical specializes in infrared-based devices for painless and rapid hemorrhoid treatment. Its FDA-cleared devices have gained significant traction in outpatient and ASC environments, with a design focus on patient comfort and fast recovery .

 

5. Karl Storz The German-based company is well-known for its endoscopy and surgical instruments . Karl Storz brings to the market high-end hemorrhoidal ligation and visualization tools, mostly used in teaching hospitals and complex cases requiring detailed diagnostics.

 

6. Ultroid Technologies, Inc. Ultroid Technologies focuses on non-invasive electrical treatment systems for hemorrhoids . Its direct-to-clinic sales model has allowed penetration into niche markets, especially in Latin America and Southeast Asia. The technology appeals to clinics aiming for zero- anesthesia , pain-free procedures .

 

7. Redfield Corporation Operating with a strong focus on ligators and anoscopic accessories , Redfield Corporation caters to mid-sized clinics and private practices. The company’s value proposition centers around cost efficiency and bulk purchase programs for high-volume practices.

 

Competitive Themes and Differentiators

• Innovation Focus: Players like Privi Medical and Ultroid are defining the next wave of low-pain, device-assisted therapy options.

• Geographic Reach: Medtronic and Cook Medical maintain strong global footprints, while startups are regionally focused.

• Regulatory Strategy: CE and FDA approval pipelines are critical benchmarks for success, with companies investing in clinical trials and product validation .

• Distribution Models: A shift toward direct-to-practice distribution is observed in emerging markets, bypassing traditional hospital channels.

• Partnership Models: Increasingly, companies are engaging in co-development initiatives with colorectal surgeons to co-design ergonomic and efficient devices.

“Competitive advantage in this market hinges on rapid treatment, minimal pain, and intuitive device design—whoever cracks this trifecta will dominate the outpatient segment,” concludes a competitive intelligence lead from a European diagnostics firm.

 

Regional Landscape And Adoption Outlook

The hemorrhoid treatment devices market exhibits marked regional differences in adoption, reimbursement, infrastructure maturity, and innovation. While North America leads in procedural volume and advanced technologies, Asia-Pacific is emerging as a high-growth region fueled by healthcare expansion and urban lifestyle shifts. Each geography presents unique challenges and opportunities for manufacturers and healthcare stakeholders.

North America

North America , led by the United States , dominates the global market, accounting for over 35% of revenue share in 2024 . High disease awareness, robust reimbursement frameworks, and a dense network of ambulatory surgical centers drive adoption.

• U.S.: The leading country by both device volume and procedure count. The popularity of rubber band ligation and infrared coagulation is especially high in outpatient GI clinics and colorectal centers .

• Canada: Slower adoption of newer technologies due to tighter regulatory cycles and more conservative insurance policies, but growth is consistent.

“In the U.S., reimbursement support and liability protection for non-surgical hemorrhoid treatments give device manufacturers a big commercial edge,” notes a payer strategy expert.

 

Europe

Europe is a mature but varied market, driven by a mix of public health systems , clinical conservatism , and a push toward non-surgical pathways .

• Germany and the UK are market leaders, supported by strong clinical infrastructure and procedure reimbursement for outpatient therapies.

• France and Italy show steady adoption but slower movement toward disposable and digital-enabled systems.

• Regulatory oversight by the EU MDR continues to influence device deployment, especially for Class II systems.

Regional initiatives, such as value-based care models , are nudging providers to prefer quick recovery devices that reduce follow-ups and complications.

 

Asia-Pacific

The Asia-Pacific region is the fastest-growing in the global hemorrhoid treatment devices market, with a projected CAGR exceeding 9% through 2030 . Urbanization, aging demographics, and changing dietary patterns are escalating the incidence of hemorrhoids across the region.

• China: Rapid growth in colorectal diagnostics and treatment centers , supported by domestic manufacturing and government health subsidies.

• India: A price-sensitive but large-volume market, with rising demand in tier-1 cities for non-invasive procedures . However, rural access remains limited.

• Japan and South Korea: High-tech infrastructure enables the uptake of advanced hemorrhoidal laser and RF systems. These countries also favor multi-functional GI platforms that include hemorrhoid therapy modules.

“Asia-Pacific is moving toward outpatient therapeutic devices at a much faster pace than anticipated, especially where health insurance schemes are expanding,” remarks a regional medtech executive.

 

Latin America

Latin America shows moderate adoption levels, restrained by economic volatility and fragmented healthcare access. However, Brazil and Mexico are emerging as hotspots due to rising obesity and digestive health awareness.

• Adoption is driven by cost-effective ligation and cryotherapy systems .

• Local distributors and public-private hospital models are key to market penetration.

 

Middle East & Africa (MEA)

The MEA region remains underserved but holds long-term potential. Current barriers include limited colorectal specialization, high procedural costs, and inconsistent device availability.

• Gulf Cooperation Council (GCC) countries such as Saudi Arabia and UAE are making strides with private hospital investments and imported technologies .

• In Africa , particularly Sub-Saharan regions, hemorrhoidal care is still heavily dependent on conventional medicine or open surgery, signaling a major white space for device manufacturers.

 

End-User Dynamics And Use Case

The hemorrhoid treatment devices market operates across a wide range of clinical environments, each with distinct procurement preferences, procedural workflows, and patient throughput requirements. Understanding these end-user dynamics is crucial for both market penetration and product design optimization.

Hospitals

Hospitals—particularly tertiary care centers and academic hospitals —represent the largest end-user group by revenue share. These institutions tend to manage complex or high-grade hemorrhoid cases and often utilize multi-modal treatment systems , including electrosurgical units and Doppler-guided ligation equipment.

Key characteristics:

• Integration with anesthesia and surgical teams

• Greater usage of reusable instruments

• Preference for multi-procedure platforms that combine colorectal diagnostics and intervention

However, decision-making is centralized and purchasing cycles are long, often requiring rigorous clinical validation and multi-departmental approvals.

 

Ambulatory Surgical Centers (ASCs)

ASCs are rapidly gaining ground, particularly in North America, Germany, South Korea, and the UAE , owing to their ability to handle high patient volumes at lower costs. The demand for disposable, ergonomic, and quick-set-up devices is particularly high in these centers .

Why ASCs matter:

• High turnover and procedural standardization

• Preference for minimal prep, anesthesia -free devices

• Shorter patient recovery periods support same-day discharge

• Key hub for infrared coagulation and band ligation treatments

“ASCs are becoming the epicenter for device-based hemorrhoid procedures because of their economic efficiency and scheduling flexibility,” says a U.S.-based surgical center administrator.

 

Specialty Clinics and Colorectal Centers

These facilities—often run by gastroenterologists or proctologists —represent a significant and fast-growing segment. Clinics typically prefer compact, portable, and procedure-specific kits that minimize training requirements and allow high procedural autonomy .

Attributes include:

• High adoption of ligators , sclerotherapy injectors, and infrared tools

• Reliance on manufacturer-provided training and support

• Often cash-based or partially reimbursed, increasing focus on cost-effective solutions

This segment is especially strong in urban centers in India, China, Brazil, and Southeast Asia , where demand is surging for outpatient colorectal care.

 

Use Case: Minimally Invasive Hemorrhoid Care in a South Korean ASC

A tertiary ambulatory surgical center in Busan, South Korea , recently adopted an infrared coagulation system designed for high turnover and low patient discomfort. Prior to adoption, the facility faced frequent follow-up visits and complaints of post-procedural pain with traditional band ligation.

With the new device:

• Procedure time was reduced by 40%

• Post-treatment complications dropped by 60%

• The number of repeat visits per patient fell from 2.4 to 1.1

• Patient satisfaction scores increased significantly

“Our ASC has become a regional referral center for hemorrhoid treatment within six months, purely based on our shift to a precision-based, painless procedure model,” reported the clinic’s lead proctologist.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Past 2 Years)

The hemorrhoid treatment devices market has witnessed a series of impactful developments over the past 24 months, reflecting rising investor confidence, regulatory acceleration, and global demand expansion.

• Privi Medical received expanded FDA clearance for its updated infrared coagulation platform, optimized for same-day outpatient procedures with enhanced patient comfort and digital treatment tracking.

• Ultroid Technologies launched a new direct-to-clinic training program across Southeast Asia, targeting independent GI practices and accelerating adoption of non-surgical hemorrhoid devices.

• Cook Medical expanded its hemorrhoid product distribution into Eastern Europe through strategic partnerships with local surgical supply distributors, improving regional availability.

• Redfield Corporation introduced a line of pre-packaged single-use hemorrhoid ligator kits in collaboration with outpatient surgery centers , aiming to cut down procedure setup time by 30%.

• Korean-based endoscopic startup HemoTech secured Series A funding to develop AI-assisted diagnostic anoscopes integrated with real-time tissue classification and treatment recommendations.

 

Opportunities

1. Emerging Market Penetration Rapid urbanization, rising fiber -deficient diets, and expanded insurance schemes are creating high-volume opportunities in India, Southeast Asia, and Latin America . Strategic local partnerships and price-tiered product lines can unlock exponential growth.

2. Growth in Ambulatory and Outpatient Settings The global shift to ambulatory care is accelerating demand for portable, disposable, and anesthesia -free hemorrhoid treatment devices. ASCs and specialized GI clinics present an ideal target for companies with efficient, single-use solutions.

3. Device Personalization and AI Integration Future market leaders will offer smart, responsive treatment platforms that adjust thermal output, tissue engagement, or application pressure based on patient-specific anatomy and hemorrhoid grade—creating a major frontier for innovation.

 

Restraints

1. Regulatory Delays in Emerging Markets While developed nations offer streamlined approval for Class II devices, several emerging markets face complex, underfunded regulatory systems , delaying product registration and importation.

2. Limited Specialist Access in Rural Regions In lower-income and rural areas, there’s a pronounced lack of colorectal surgeons and GI specialists , leading to underutilization of advanced devices and continued reliance on traditional surgical methods.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 795.3 Million
Revenue Forecast in 2030	USD 1.66 Billion
Overall Growth Rate	CAGR of 13.2% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Procedure, By End User, By Geography
By Product Type	Band Ligators, Infrared Coagulators, Cryotherapy, Sclerotherapy, Electrosurgical Equipment, DG-HAL Systems
By Procedure	Non-Surgical, Minimally Invasive Surgical, Conventional Hemorrhoidectomy
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, GCC countries
Market Drivers	- Rise in outpatient colorectal procedures - Preference for non-invasive treatments - Growing GI disorder prevalence
Customization Option	Available upon request